The prices for active pharmaceuticals ingredients (API) will recover in FY27 due to the implementation of minimum import price (MIP) starting from 29 January 2026 and China’s withdrawal value-added ...

On Sept. 5, the FDA announced an import alert and green list for glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredient (API) manufacturers. The FDA included manufacturers on the green list ...

The FDA released a warning letter sent to Chinese API maker Qinhuangdao Zizhu Pharmaceutical in April that outlined data integrity problems at the company’s Hebei province facility following an ...

In a significant regulatory development aimed at controlling substandard imports, the Government of India has imposed price-based import restriction on sulfadiazine API, a key active pharmaceutical ...